Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation
KM Sullivan(University of Washington), F R Appelbaum(City Of Hope National Medical Center), Paul J. Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jan‐Stephan Sanders(Tufts University), Howard M. Shulman(Fred Hutch Cancer Center), A Klosterman(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), D. B. Amos(Florida College), Robert Witherspoon(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), George Sale(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), H. Joachim Deeg(Fred Hutch Cancer Center)
Cited by 163
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968